Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-03-05 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of a management participation in a conference. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events. The content is an announcement of an upcoming event (conference schedule) rather than a report or detailed financial data. It does not contain financial statements, audit information, voting results, or any other detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the schedule of analyst and institutional investor meetings. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document is short (2369 characters) and serves as an announcement of the upcoming investor meetings and the availability of the presentation, rather than containing the presentation itself or detailed financial data. It is submitted pursuant to SEBI Listing Regulations, indicating a regulatory announcement. Therefore, this document is best classified as an Investor Presentation announcement or related update. Given the options, the closest and most appropriate classification is 'Investor Presentation' (IP).
2024-03-05 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-02-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled meeting between company officials and analysts/institutional investors. It mentions that an Investor Presentation has been uploaded on the stock exchanges and the company's website. The document is short (2342 characters) and serves as an announcement of the upcoming investor meeting and the availability of the presentation, rather than containing the presentation itself or detailed financial data. Therefore, it is an announcement related to investor communication, specifically about an investor presentation event and the availability of the presentation, fitting the category of Investor Presentation (IP). However, since the document itself does not contain the presentation but only announces the schedule and availability, it aligns best with the Investor Presentation category as it is focused on investor communication and presentation scheduling.
2024-02-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of a management conference participation. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events. The content is an announcement of a management event (conference schedule) rather than a report or detailed financial document. It does not contain financial data, audit information, voting results, or any other report type content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings call held on February 8, 2024, discussing the financial and operational performance of Supriya Lifescience Limited for the quarter and nine months ended December 31, 2023. It includes management commentary, financial highlights, and a Q&A session with analysts. The presence of detailed financial figures, management discussion, and Q&A confirms this is a full transcript of the earnings call rather than a brief earnings release or a presentation. The document is about 15,000 characters long, indicating it is a full transcript and not just an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2024-02-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.